PharmaVentures appoints senior director

Paul Phull will develop corporate advisory business

PharmaVentures, based in Oxford, UK, has hired Paul Phull as senior director to develop its corporate advisory business.

PharmaVentures is an international corporate advisory firm supporting its clients’ growth ambitions through licensing, joint ventures and M&A in the healthcare industry. The company works for a variety of clients from start-ups to global pharmaceutical corporations, their advisers, investment companies and government bodies.

Phull joins the company from Sinclair Pharma, a specialist pharmaceutical company in the UK, where he was responsible for the development of the international business. He has significant deal making and corporate transaction experience with a broad range of companies in Europe, US, Japan, India and Asia in a number of therapeutic areas.

You may also like

Finance

Cambrex unveils $120m investment to expand API manufacturing and strengthen US drug supply resilience

Cambrex's continued investments underscore its commitment to adding capabilities and increasing capacity to meet the evolving needs and growing demand of the pharmaceutical industry.
Finance

Curia invests $4m to enhance sterile API manufacturing

The investment aligns with the latest EU GMP Annex 1 standards and reinforces Curia’s longstanding commitment to regulatory excellence and product quality
Finance

Agarose Bead Technologies marks 25 years with $10m global expansion plan

The Spanish agarose resin specialist will expand into the US and India, invest in scalable bioprocessing technologies and enhance sustainability across its European facilities to meet growing demand for advanced therapy purification
Packaging

Sharp Services invests $100m to expand global sterile and packaging capacity across US and Europe

The investment will boost sterile fill/finish, injectable packaging and oral solid dose capacity across Sharp's US and European sites, strengthening its clinical and commercial manufacturing network to meet growing pharmaceutical demand
Finance

MilliporeSigma to acquire JSR Life Sciences’ chromatography business, boosting Protein A purification capabilities

The acquisition expands MilliporeSigma’s downstream bioprocessing portfolio with JSR’s Amsphere Protein A resin technology, enhancing efficiency and reliability in monoclonal antibody and therapeutic protein production
Finance

Wilmington PharmaTech secures further funding for its expansion from Curewell Capital

The CDMO's partnership with Curewell will provide significant growth capital to expand WPT’s manufacturing capacity and further scale its end-to-end capabilities in producing a full range of small molecule API in the US
Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Subscribe now